Overview

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2029-05-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou BlueHorse Therapeutics Co., Ltd.